Recovery and Half-Life of von Willebrand Factor-Cleaving Protease after Plasma Therapy in Patients with Thrombotic Thrombocytopenic Purpura

Miha Furlan; Rodolfo Robles; Beat Morselli; Pierre Sandoz; Bernhard Lämmle

doi:10.1055/s-0037-1614408

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1999; 81(01): 8-13
DOI: 10.1055/s-0037-1614408

Review Article

Schattauer GmbH

Recovery and Half-Life of von Willebrand Factor-Cleaving Protease after Plasma Therapy in Patients with Thrombotic Thrombocytopenic Purpura

Miha Furlan

²From the Central Hematology Laboratory, University Hospital, Inselspital, Bern, and Bürgerspital Solothurn, Switzerland

,

Rodolfo Robles

²From the Central Hematology Laboratory, University Hospital, Inselspital, Bern, and Bürgerspital Solothurn, Switzerland

,

Beat Morselli

¹From the Central Hematology Laboratory, University Hospital, Inselspital, Bern, Switzerland

,

Pierre Sandoz

¹From the Central Hematology Laboratory, University Hospital, Inselspital, Bern, Switzerland

,

Bernhard Lämmle

²From the Central Hematology Laboratory, University Hospital, Inselspital, Bern, and Bürgerspital Solothurn, Switzerland

› Author Affiliations

References
1 Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-5.
2 Chow TW, Turner NA, Chintagumpala M, McPherson PD, Nolasco LH, Rice L, Hellums JD, Moake JL. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol 1998; 57: 293-302.
3 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stre-induced platelet aggregation. J Clin Invest 1986; 78: 1456-61.
4 Tsai HM, Sussman I I, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994; 83: 2171-9.
5 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
6 Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-44.
7 Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand disease. Proc Natl Acad Sci USA 1990; 87: 6306-10.
8 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103.
9 Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91: 2839-46.
10 Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977; 297: 1386-9.
11 Shepard KV, Bukowski RM. The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange. Semin Hematol 1987; 24: 178-93.
12 Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863
13 Feldschuh J, Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 1977; 56: 605-12.
14 Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. and members of the CASG. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393-7.
15 Gaddis TG, Guthrie TH, Drew MJ, Sahud M, Howe RB, Mittelman A. Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption. Am J Hematol 1997; 55: 55-8.
16 Moake JL, Byrnes JJ, Troll JH, Rudy CK, Hong SL, Weinstein MJ, Colannino NM. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1985; 65: 1232-6.
17 Frangos JA, Moake JL, Nolasco L, Phillips MD, McIntite LV. Cryosupernatant regulates accumulation of unusually large vWF multimers from endothelial cells. Am J Physiol 1989; 256: H-1635-44.
18 Moake JL. Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Semin Hematol 1997; 34: 83-9.
19 Gonias SL, Pizzo SV. Reaction of human α2-macroglobulin half-molecules with plasmin as a probe of protease binding site structure. Biochemistry 1983; 22: 4933-40.
20 Seligsohn U, Kasper CK, Østerud B, Rapaport I. S. Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1978; 53: 828-37.